EA201691496A1 - Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток - Google Patents

Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток

Info

Publication number
EA201691496A1
EA201691496A1 EA201691496A EA201691496A EA201691496A1 EA 201691496 A1 EA201691496 A1 EA 201691496A1 EA 201691496 A EA201691496 A EA 201691496A EA 201691496 A EA201691496 A EA 201691496A EA 201691496 A1 EA201691496 A1 EA 201691496A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ctc
crpc
subpopulation
prevalence
tumor cells
Prior art date
Application number
EA201691496A
Other languages
English (en)
Inventor
Райан Диттамор
Original Assignee
Эпик Сайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпик Сайенсиз, Инк. filed Critical Эпик Сайенсиз, Инк.
Publication of EA201691496A1 publication Critical patent/EA201691496A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G01N2021/6441—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks with two or more labels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Abstract

Настоящее изобретение описывает способ детектирования кастрационно-резистентного рака предстательной железы (CRPC) у пациента, страдающего от рака предстательной железы, содержащий: (а) осуществление непосредственного анализа, содержащего иммунофлуоресцентное окрашивание и морфологическую характеризацию ядросодержащих клеток в образце крови, полученном от пациента, для детектирования циркулирующих опухолевых клеток (СТС), (b) определение распространенности субпопуляции СТС, связанной с CRPC, содержащее детектирование измеримого признака каждого биомаркера в панели морфологических и белковых биомаркеров, и (с) сравнение распространенности упомянутой субпопуляции СТС с предварительно определенным пороговым значением, причем распространенность субпопуляции СТС, связанной с CRPC, выше упомянутого предварительно определенного порогового значения является признаком CRPC. В некоторых вариантах осуществления субпопуляция СТС, связанная с CRPC, содержит CK-СТС. В некоторых вариантах осуществления субпопуляция СТС, связанная с CRPC, содержит маленькие СТС. В дополнительных вариантах осуществления способы настоящего изобретения дополнительно содержат молекулярный анализ СТС.
EA201691496A 2014-01-27 2015-01-26 Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток EA201691496A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461932096P 2014-01-27 2014-01-27
PCT/US2015/012858 WO2015112955A1 (en) 2014-01-27 2015-01-26 Circulating tumor cell diagnostics for prostate cancer biomarkers

Publications (1)

Publication Number Publication Date
EA201691496A1 true EA201691496A1 (ru) 2016-12-30

Family

ID=53682011

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691496A EA201691496A1 (ru) 2014-01-27 2015-01-26 Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток

Country Status (4)

Country Link
US (2) US10527624B2 (ru)
EP (1) EP3100047B1 (ru)
EA (1) EA201691496A1 (ru)
WO (1) WO2015112955A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050103A1 (en) 2009-10-21 2011-04-28 The Scripps Research Institute Method of using non-rare cells to detect rare cells
WO2015112955A1 (en) 2014-01-27 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
EP3108246B1 (en) 2014-02-21 2019-10-09 Epic Sciences, Inc. Methods for analyzing rare circulating cells
JP6936231B2 (ja) * 2015-09-25 2021-09-15 エピック サイエンシス， インコーポレイテッド 転移性去勢抵抗性前立腺癌（ｍＣＲＰＣ）患者における治療選択のためのバイオマーカーとしてのアンドロゲン受容体バリアント７
EP3359692A4 (en) * 2015-10-05 2019-05-01 Cedars-Sinai Medical Center METHOD OF CLASSIFYING AND DIAGNOSING CANCER
EA201891085A1 (ru) * 2015-11-03 2018-11-30 Эпик Сайенсиз, Инк. Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания
CA3010311A1 (en) * 2016-01-06 2017-07-13 Epic Sciences, Inc. Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
US11514289B1 (en) * 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
US20220260574A1 (en) * 2017-06-02 2022-08-18 Epic Sciences, Inc. Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease
US11727699B2 (en) * 2017-10-05 2023-08-15 Becton, Dickinson And Company Application development environment for biological sample assessment processing
TWI784163B (zh) * 2019-04-23 2022-11-21 長庚大學 用於純化分離及分析腫瘤表面標記陰性且血球表面標記陰性之有核細胞的方法及腫瘤表面標記陰性且血球表面標記陰性之有核細胞之應用
CN117580962A (zh) * 2021-05-19 2024-02-20 动量生物技术有限公司 通过基因表达分析检测肾脏疾病或受损的方法和系统

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3830721A1 (de) 1988-09-09 1990-03-22 Michael Dr Menton In labors, insbesondere in medizinischen labors, zu verwendender objekttraeger
US6197523B1 (en) 1997-11-24 2001-03-06 Robert A. Levine Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood
CA2253965C (en) 1997-11-22 2003-01-21 Robert A. Levine Method for the detection, identification, enumeration and confirmation of circulating cancer cells and/or hematologic progenitor cells in whole blood
US8192994B2 (en) 1998-02-10 2012-06-05 Angros Lee H Method of applying a biological specimen to an analytic plate
EP1062515B1 (en) 1998-02-12 2009-11-25 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO1999058972A1 (en) 1998-05-09 1999-11-18 Ikonisys Inc. Method and apparatus for computer controlled rare cell, including fetal cell, based diagnosis
US6960449B2 (en) 1999-02-10 2005-11-01 Cell Works Diagnostics, Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
US7546210B2 (en) 2000-06-08 2009-06-09 The Regents Of The University Of California Visual-servoing optical microscopy
US7033832B2 (en) 2000-10-13 2006-04-25 University Of Medicine And Dentistry Of New Jersey Endothelial cell—cell cohesion
WO2002061387A2 (en) 2000-10-25 2002-08-08 Exiqon A/S Open substrate platforms suitable for analysis of biomolecules
US6701197B2 (en) 2000-11-08 2004-03-02 Orbotech Ltd. System and method for side to side registration in a printed circuit imager
US20080009019A1 (en) 2001-06-13 2008-01-10 Smithkline Beecham Corporation High throughput method for screening candidate compounds for biological activity
US7863012B2 (en) 2004-02-17 2011-01-04 Veridex, Llc Analysis of circulating tumor cells, fragments, and debris
JP2005502863A (ja) 2001-08-23 2005-01-27 イムニベスト・コーポレイション 循環腫瘍細胞、断片およびデブリスの分析
US7943093B2 (en) 2001-12-12 2011-05-17 Erie Scientific Company Cover slip
WO2003069421A2 (en) 2002-02-14 2003-08-21 Immunivest Corporation Methods and algorithms for cell enumeration in a low-cost cytometer
US7113624B2 (en) 2002-10-15 2006-09-26 Palo Alto Research Center Incorporated Imaging apparatus and method employing a large linear aperture
US7305112B2 (en) 2002-10-15 2007-12-04 The Scripps Research Institute Method of converting rare cell scanner image coordinates to microscope coordinates using reticle marks on a sample media
US7282180B2 (en) 2003-07-02 2007-10-16 Immunivest Corporation Devices and methods to image objects
US7372985B2 (en) 2003-08-15 2008-05-13 Massachusetts Institute Of Technology Systems and methods for volumetric tissue scanning microscopy
WO2005100999A2 (en) 2004-04-08 2005-10-27 Cornell Research Foundation, Inc. Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
WO2006041453A1 (en) 2004-09-30 2006-04-20 Immunivest Corporation Circulating tumor cells (ctc’s): apoptotic assessment in prostate cancer patients
EP2264512B1 (en) 2004-11-24 2014-06-04 Battelle Memorial Institute Method and apparatus for detection of rare cells
US7280261B2 (en) 2004-12-20 2007-10-09 Palo Alto Research Center Incorporated Method of scanning and light collection for a rare cell detector
US20090081688A1 (en) 2005-06-20 2009-03-26 Advanced Cell Diagnostics Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
US20070009389A1 (en) 2005-07-08 2007-01-11 Antti Seppo Slide deposition chamber
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
JP2009525468A (ja) 2006-01-30 2009-07-09 ザ・スクリプス・リサーチ・インステイチユート 循環腫瘍細胞の検出方法および哺乳類対象における癌の診断方法
WO2011050103A1 (en) 2009-10-21 2011-04-28 The Scripps Research Institute Method of using non-rare cells to detect rare cells
US8337755B2 (en) 2006-03-13 2012-12-25 Veridex, Llc Operator independent programmable sample preparation and analysis system
US20080076727A1 (en) 2006-03-29 2008-03-27 John Wayne Cancer Institute Utility of high molecular weight melanoma associated antigen in diagnosis and treatment of cancer
US20090105963A1 (en) 2006-05-13 2009-04-23 Jesper Laursen Methods for Flow Cytometry Analyses of Un-Lysed Cells from Biological Fluids
WO2007141626A1 (en) 2006-06-02 2007-12-13 Pfizer Products Inc. Circulating tumor cell assay
JP5258173B2 (ja) 2006-06-05 2013-08-07 株式会社ジャパンディスプレイ 液晶表示装置
WO2007147018A1 (en) 2006-06-14 2007-12-21 Cellpoint Diagnostics, Inc. Analysis of rare cell-enriched samples
WO2008014516A2 (en) 2006-07-28 2008-01-31 Living Microsystems, Inc. Selection of cells using biomarkers
CN101606060A (zh) 2006-09-05 2009-12-16 维里德克斯有限责任公司 细胞图像的归类方法
US8244021B2 (en) 2006-12-20 2012-08-14 Ventana Medical Systems, Inc. Quantitative, multispectral image analysis of tissue specimens stained with quantum dots
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
EP2155856A4 (en) 2007-06-05 2013-06-26 Nanopoint Inc SYSTEMS AND METHODS OF CELL TRAY
EP2201134B1 (en) 2007-09-19 2018-11-21 The Research Foundation of State University of New York Gene expression signatures in enriched tumor cell samples
WO2009051734A1 (en) 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
US8088715B2 (en) 2007-11-13 2012-01-03 Ikonisys, Inc. Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope
US20090258365A1 (en) 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
US20110189670A1 (en) 2008-07-07 2011-08-04 Ruth L Katz Circulating Tumor and Tumor Stem Cell Detection Using Genomic Specific Probes
US9779213B2 (en) 2008-07-25 2017-10-03 Fundacao D. Anna Sommer Champalimaud E Dr. Carlos Montez Champalimaud System for evaluating a pathological stage of prostate cancer
US8324280B2 (en) 2008-08-07 2012-12-04 The University Of British Columbia Treatment of prostate cancer with DDC inhibitor
US8445225B2 (en) 2008-09-05 2013-05-21 The Scripps Research Institute Methods for the detection of circulating tumor cells
US20130209493A1 (en) 2010-01-27 2013-08-15 Mariano Garcia-Blanco Biomakers for circulating tumor cells
CA2791244A1 (en) 2010-03-08 2011-09-15 Regents Of The University Of Minnesota Androgen receptor isoforms and methods
TWI539158B (zh) 2010-06-08 2016-06-21 維里德克斯有限責任公司 使用血液中之循環黑色素瘤細胞預測黑色素瘤病患之臨床結果的方法。
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
EP3564395A1 (en) 2010-12-30 2019-11-06 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
AU2012209329A1 (en) 2011-01-24 2013-09-12 Epic Sciences, Inc. Methods for obtaining single cells and applications of single cell omics
EP2729802B1 (en) 2011-07-07 2015-05-06 Scripps Health Method of analyzing cardiovascular disorders and uses thereof
WO2013049926A1 (en) 2011-10-06 2013-04-11 UNIVERSITé LAVAL PROGNOSTIC MARKERS OF INHERITED VARIATIONS IN THE 17β-HYDROXYSTEROID DEHYDROGENASE (HSD17B) GENES FOR PROSTATE CANCER
AU2012347526A1 (en) 2011-12-09 2014-07-10 Gerd MARIENFELD Apparatus, system and method for identifying circulating tumor cells
DK2798355T3 (en) * 2011-12-30 2018-12-03 Ventana Med Syst Inc Automated analysis of circulating tumor cells
AU2013213301A1 (en) 2012-01-24 2014-07-17 Epic Sciences, Inc. Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject
CA2874691C (en) 2012-06-01 2021-08-24 Creatv Microtech, Inc. Capture, identification and use of a new biomarker of solid tumors in body fluids
WO2014008155A1 (en) 2012-07-02 2014-01-09 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
US20140024024A1 (en) 2012-07-17 2014-01-23 General Electric Company Methods of detecting dna, rna and protein in biological samples
US9671405B2 (en) 2012-09-19 2017-06-06 Cornell University Identifying taxane sensitivity in prostate cancer patients
EP2912194B1 (en) 2012-10-26 2019-05-08 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
CN105102978B (zh) 2013-02-02 2018-11-02 杜克大学 分离循环肿瘤细胞的方法
BR112015023120A2 (pt) 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
US20160266127A1 (en) 2013-09-30 2016-09-15 Peter Kuhn Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
US20150147339A1 (en) 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
US20170192003A1 (en) 2013-12-03 2017-07-06 The Scripps Research Institute Compositions and methods for fluid biopsy of melanoma
WO2015103039A1 (en) 2013-12-30 2015-07-09 The Scripps Research Institute Circulating tumor cell diagnostics for lung cancer
WO2015112955A1 (en) 2014-01-27 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
EP3099821B1 (en) 2014-01-27 2021-08-11 Epic Sciences, Inc. Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)
US20160011198A1 (en) 2014-01-27 2016-01-14 Epic Sciences, Inc. Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
EP3100052B1 (en) 2014-01-30 2021-03-10 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies
WO2015116780A1 (en) 2014-01-31 2015-08-06 Epic Sciences, Inc. Methods for the detection and quantification of circulating tumor cell mimics
EP3108246B1 (en) 2014-02-21 2019-10-09 Epic Sciences, Inc. Methods for analyzing rare circulating cells
ES2869866T3 (es) 2014-09-25 2021-10-26 Epic Sciences Inc Diagnóstico mediante células tumorales circulantes para la identificación de la resistencia a las terapias selectivas del receptor de andrógenos
US20170242016A1 (en) 2014-10-15 2017-08-24 Epic Sciences, Inc. Circulating tumor cell diagnostics for therapy targeting pd-l1
US20180155794A1 (en) 2015-05-29 2018-06-07 Epic Sciences, Inc. Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)
EA201891085A1 (ru) 2015-11-03 2018-11-30 Эпик Сайенсиз, Инк. Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания
CA3010311A1 (en) 2016-01-06 2017-07-13 Epic Sciences, Inc. Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity

Also Published As

Publication number Publication date
US20160033508A1 (en) 2016-02-04
WO2015112955A1 (en) 2015-07-30
EP3100047A4 (en) 2017-08-16
US10527624B2 (en) 2020-01-07
EP3100047B1 (en) 2021-08-11
EP3100047A1 (en) 2016-12-07
US20200333345A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
EA201691496A1 (ru) Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EA201691505A1 (ru) Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc)
EA201691499A1 (ru) Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
MX2020004567A (es) Metodos diagnosticos y terapeuticos para el cancer.
EA201891571A1 (ru) Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
WO2015128272A3 (en) Photo-selective method for biological sample analysis field
GB2531881A (en) Method of isolating circulating tumor cells
MY198081A (en) Urinalysis device and dry reagent for quantitative urinalysis
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
WO2014144129A3 (en) Biomarkers and methods for predicting preterm birth
EA201691352A1 (ru) Диагностика рака легкого с помощью циркулирующих опухолевых клеток
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
WO2014065889A3 (en) Multiplexed method for diagnosing classical hodgkin lymphoma
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
EA201691497A1 (ru) Способы детектирования и количественного определения имитаторов циркулирующих опухолевых клеток
EA201691682A1 (ru) Способы анализирования редких циркулирующих в крови клеток
ES2530734T3 (es) Biomarcador en suero bioquímico
WO2018097614A3 (ko) 유방암 환자의 화학치료 유용성 예측 방법
MX2015012319A (es) Sistemas de instrumento analitico.
MX2019006098A (es) Ensayo de anticuerpos.
MX2019002918A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
BR112018010764A2 (pt) método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente
WO2016198833A3 (en) Methods for analysing a urine sample